Welcome to our dedicated page for Zai Lab news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab stock.
Zai Lab Limited (ZLAB) is a research-based, commercial-stage biopharmaceutical company based in China and the United States, with a focus on oncology, immunology, neuroscience, and infectious disease. The Zai Lab news feed on Stock Titan aggregates company announcements, clinical updates, regulatory milestones, and financial disclosures that the company releases through channels such as Business Wire and SEC filings.
Investors and followers of ZLAB stock can use this page to review news on Zai Lab’s global pipeline, including progress of assets like zocilurtatug pelitecan (zoci), a DLL3-targeted antibody-drug conjugate for extensive-stage small cell lung cancer and other neuroendocrine carcinomas, and ZL-1503, an IL-13/IL-31R bispecific antibody for atopic dermatitis. Updates on other oncology and immunology programs, such as ZL-6201, ZL-1222, and ZL-1311, also appear in company press releases.
The news stream highlights regulatory developments in Greater China, including National Medical Products Administration (NMPA) approvals and National Reimbursement Drug List (NRDL) decisions for products in Zai Lab’s commercial portfolio. Recent examples include announcements about COBENFY for schizophrenia and AUGTYRO for ROS1-positive non-small cell lung cancer and NTRK-positive solid tumors, as well as renewals and coverage decisions for VYVGART, NUZYRA, and ZEJULA.
In addition, this page surfaces Zai Lab’s financial result releases, conference call notices, and participation in healthcare and investor conferences. These items provide context on revenue trends, R&D spending, and the company’s dual-engine strategy combining a China commercial business with a global innovation platform. Bookmark this page to quickly access ZLAB-related news, organized in one place for efficient review of the company’s ongoing clinical, regulatory, and corporate developments.
Zai Lab Limited (NASDAQ: ZLAB) announced its participation in three upcoming virtual conferences in June. Dr. Samantha Du, the CEO, will present at the Jefferies Global Healthcare Conference on June 2, the Goldman Sachs Annual Global Healthcare Conference on June 11, and participate in a panel at the JP Morgan China Investor Conference on June 24. Webcasts will be available live and archived on Zai Lab's website. The company focuses on developing medicines for cancer, infectious, and autoimmune diseases, aiming to establish a global pipeline of innovative drug candidates.
Zai Lab Limited (NASDAQ: ZLAB) has commenced the Phase 3 ATTACK trial, evaluating the combination of sulbactam and durlobactam (SUL-DUR) against carbapenem-resistant Acinetobacter baumannii infections. This global trial includes around 300 patients and aims to address the rising incidence of these infections in China, where over 200,000 cases occur annually. The trial's data readout is anticipated in early 2021. The combination has shown positive in-vitro activity and safety in prior studies, marking a crucial step in combating multidrug-resistant infections.
Zai Lab has obtained marketing approval from the China National Medical Products Administration (NMPA) for Optune, a novel treatment for glioblastoma. This marks the first new treatment for glioblastoma in over 15 years in China. Clinical studies demonstrated that combining Optune with temozolomide more than doubled the five-year overall survival rate for newly diagnosed patients. The approval reinforces Zai Lab's position in the biopharmaceutical market, being its second product approval in six months.
Zai Lab (NASDAQ: ZLAB) announced that the Center for Drug Evaluation of China's NMPA has granted priority review status to its New Drug Application for omadacycline, targeting community-acquired bacterial pneumonia (CABP) and acute bacterial skin infections (ABSSSI). This designation aims to expedite the drug's approval process, addressing unmet medical needs in China related to bacterial resistance. Omadacycline, launched in the U.S. in February 2019, is designed to combat a broad range of bacterial infections, including multi-drug-resistant strains.
Summary not available.